IL17A and psoriasis vulgaris: We longitudinally analyzed 152 patients with plaque psoriasis, 2. Inactivated SARS‐CoV‐2 vaccine has no major impact on the safety and efficacy of biologics (TNF‐α inhibitor or IL‐17A inhibitor) in patients with moderate to severe plaque psoriasis.